hVIVO (HVO) Share Price, News & Analysis

Company Overview

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Key Stats

• Today's Range: 7.26 to 7.50
• 50-Day Range: 6.60 to 8.95
• 52-Week Range: 4.31 to 11.30
• Volume: 297,255 shs
• Average Volume: 2.79 million shs
• Market Capitalization: £49.94 million
• P/E Ratio: N/A
• Dividend Yield: 2.68%
• Price Target: GBX 15
• Consensus Rating: Moderate Buy

Company Calendar

• Last Earnings: 4/15/2026
• Today: 8/03/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: LON:HVO
• Previous Symbol: LON:RVG
• CIK: N/A
• Web: hvivo.com
• Phone: +44-20-77561300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for hVIVO: GBX 15
• High Price Target: GBX 25
• Low Price Target: GBX 10
• Potential Upside/Downside: +106.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 4.68
• P/E Growth: N/A
• Net Income: £17.84 million
• Net Margins: -12.48%
• Pretax Margin: N/A
• Return on Equity: -14.65%
• Return on Assets: 11.97%

Debt

• Debt-to-Equity Ratio: 38.75
• Current Ratio: 1.63
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: £46.77 million
• Price / Sales: 1.07
• Cash Flow: GBX 1.47 per share
• Price / Cash Flow: 4.94
• Book Value: GBX 5.56 per share
• Price / Book: 1.30

Miscellaneous

• Outstanding Shares: 688,401,000
• Free Float: N/A
• Market Cap: £49.94 million
• Optionable: Not Optionable
• Beta: 1.71